Paris +

Adrien Starck est spécialisé en droit des sociétés. Il représente des entreprises françaises et internationales dans le cadre de leurs opérations de fusions-acquisitions domestiques et transfrontalières, dans des secteurs variés.


  • Affinity Partners leads €207 million Series F financing of EGYMJones Day represented Affinity Partners in its acquisition of an interest in EGYM, a global fitness technology and corporate health innovation leader, in a Series F financing of €107 million, with an additional €100 million available for future investments.
  • Elaia Partners invests in GreenbidsJones Day advised Elaia Partners in its participation in the €1.6 million financing of Greenbids, a cutting-edge French adtech company dedicated to reducing carbon emissions in the digital advertising industry.
  • DIC acquires photoresist polymers manufacturer PCAS CanadaJones Day advised DIC Corporation, a Japanese chemicals group operating globally in over 60 countries, in connection with its acquisition of Quebec-based PCAS Canada Inc., a company that manufactures and sells polymers used in photoresists for semiconductor photolithography, from PCAS S.A., a French company.
  • Hi Inov and Crédit Mutual Innovation lead €20 million Series A financing of Glopal S.A.S.Jones Day advised the investors Hi Inov, Crédit Mutual Innovation, Seventure, and Axeleo in the €20 million Series A financing of Glopal S.A.S., a French software editor specialized in software for e-commerce businesses, enabling such businesses to sell their products and services globally, via their own e-commerce website, based on solutions for online international marketing, international delivery, import-export tax management, and e-commerce sites localization.
  • Lithium de France raises €44 million in Series B financingJones Day advised Lithium de France, first independent French operator of geothermal heat and lithium, in connection with its €44 million Series B financing subscribed by its main shareholders, Arverne Group, Equinor Ventures AS, and a new investor Hydro Energi Invest AS.
  • Uniphore Technologies acquires HexagonJones Day advised Uniphore Technologies, a provider of conversational artificial intelligence and automation, in the acquisition of Hexagone, which fuses voice, visual, and text-based data to provide AI-derived insights to help better understand human behavior.
  • Sanofi sells two established product portfolios to NeuraxpharmJones Day advised Sanofi in the sale of 2 portfolios of products for central nervous systems disorders and pain and vascular diseases to LESVI, a Spanish subsidiary of Neuraxpharm.
  • Lagardère Travel Retail renews JV with Groupe ADPJones Day advised Lagardère Travel Retail in the renewal of its joint venture with Aeroports de Paris including the acquisition of a 49% interest in Extime.
  • Amolyt Pharma raises $138 million in Series C financingJones Day advised Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, in connection with its $138 million Series C financing led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG), along with Tekla Capital Investment LLC, and CTI Life Sciences as well as existing investors, including, Andera Partners, Kurma, Bpifrance (Innobio), Sectoral, and Pontifax.
  • Swile and Groupe BPCE to combine to create global leader in employee benefitsJones Day advised Swile, a worktech unicorn, in the acquisition of Bimpli, a subsidiary of Groupe BPCE and leader in employee services and benefits in France.
  • Sanofi divests IMOJEV® to SUBSTIPHARMJones Day advised Sanofi in the sale of the Japanese Encephalitis vaccine IMOJEV® to SUBSTIPHARM, a privately held pharmaceutical group.
  • Karos takes over goFLUXJones Day advised Karos, French leader in carpooling services, in connection with its acquisition of goFLUX, the German carpooling app with a matching algorithm which determines a suitable meeting point for drivers and passengers.
  • Sanofi sells anti-infective portfolio to ADVANZ PHARMAJones Day advised Sanofi in the sale of a portfolio made up of eight anti-infectives including Azactam™, Cefotax™, Claforan™, Oroken™, Rulid™, Suprax™, Wintriaxone™ and Colistimethate Sodique products, which are critical in treating a broad range of infections, to ADVANZ PHARMA Corp. Limited, a UK-headquartered global pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals.
  • USERCUBE acquired by NetwrixJones Day advised the shareholders of USERCUBE in its sale to Netwrix.
  • Stride.VC and Project A invest €7 million in Hors NormesJones Day represented Stride.VC LLP and Project A in the €7 million seed round of financing of Hors Normes, a Paris-based startup that aims to prevent food waste by selling fruits and vegetables rejected by traditional retail channels.
  • Deezer merges with and into I2PO S.A.Jones Day advised Deezer S.A. in the context of the SPAC transaction whereby Deezer S.A. merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Castor raises $23.5 million in Series A financingJones Day represented Castor SAS, data catalog platform, in its $23.5 million Series A financing round led by Blossom.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • Kalray acquires Arcapix Holdings Ltd.Jones Day advised Kalray in the acquisition of Arcapix Holdings Ltd, a UK headquartered company that offers high-performance storage and data management solutions for intensive and critical data.
  • Sanofi sells 10 established products to CheplapharmJones Day advised Sanofi in the sale of a portfolio of pharmaceutical products to Cheplapharm Arzneimittel GmbH, a German privately-owned company headquartered in Greifswald, Germany.